시장보고서

상품코드

1666225

치료용 백신 시장 규모 및 예측(2021-2031년) : 세계 및 지역 점유율, 동향, 성장 기회 분석 - 제품별, 기술별, 최종사용자별, 지역별

Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography

발행일: 2025년 02월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 207 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치료용 백신 시장 규모는 2024년 12억 4,000만 달러에서 2031년까지 29억 3,000만 달러로 성장할 것으로 예상되며, 2024년부터 2031년까지 13.0%의 연평균 복합 성장률(CAGR)을 보일 전망입니다. 만성 질환의 유병률 증가, 백신 개발에 대한 투자 및 자금 조달 증가는 치료용 백신 시장 규모 확대에 기여하는 주목할 만한 요인입니다. 그러나 규제 이슈는 치료용 백신 시장의 성장을 저해하는 요인으로 작용하고 있습니다.

팬데믹을 유발할 수 있는 신종 병원체에 대한 백신 개발은 기존 기술로는 불가능합니다. 따라서, 전염병의 위협에 신속하게 대응하고 신종 변종에 효과적으로 대응할 수 있는 플랫폼을 개발하는 것이 중요합니다. mRNA 백신, 면역물질 기반 백신 기술, 나노 약물 전달 시스템, 바이러스 벡터 기반 백신 등 혁신적인 백신 플랫폼은 치료 백신 개발에 혁명을 일으키고 있습니다. 플랫폼은 치료용 백신 개발에 혁명을 일으키고 있습니다. 또한, 보다 효율적이고 맞춤화된 백신 기술로의 전환은 암, 자가면역질환, 감염성 질환을 포함한 여러 질병을 표적으로 하는 백신의 개발을 가능하게 하고 있습니다. mRNA 백신 기술 코로나19의 성공은 암과 만성 감염을 포함한 감염성 질환 이외의 치료용 mRNA 기술의 잠재력을 보여줍니다. 가능성을 보여주고 있습니다. 이러한 플랫폼은 더 빠르고, 더 유연하고, 더 확장 가능한 백신 제조를 가능하게 하여 새로운 치료용 백신의 개발을 가속화할 수 있습니다.

연구 개발자들은 미래의 응용을 위해 새로운 플랫폼을 개발하고 있습니다. 예를 들어, 하버드 대학교 Wyss 연구소 연구팀은 OMNIVAX로 알려진 선구적인 백신 플랫폼을 개발하고 있습니다. 이 '퍼스트 인 클래스 면역물질 기반' 백신 기술은 바이러스 및 세균 감염에 대한 안전하고 효과적인 치료 및 예방 백신을 만드는 것을 목표로 하고 있습니다. OMNIVAX 백신은 주사를 맞으면 수지상 면역세포를 끌어들이는 발판을 만들어 특정 항원을 표적으로 삼도록 프로그램되어 있습니다. 이후 세포가 방출되어 인근 림프절로 이동하여 전신적이고 장기적인 면역 반응을 시작하게 됩니다. 모듈화 기술을 통해 여러 항원을 하나의 OMNIVAX 백신에 통합할 수 있습니다. 백신 기술의 발전은 향후 몇 년동안 치료용 백신 시장에 새로운 트렌드를 가져올 것으로 예상됩니다.

최종 사용자 기반 인사이트

최종 사용자에 따라 치료용 백신 시장은 병원, 클리닉, 기타로 분류되며, 2024년에는 병원 부문이 치료용 백신 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 치료용 백신은 암 및 기타 만성 질환의 치료에 필수적인 것으로 인식되고 있으며, 병원 환경에서 관리되는 경우가 많습니다. 병원은 암 및 자가면역질환에 대한 전문적인 치료를 시행하는 데 필요한 고도의 인프라를 갖추고 있습니다. 암을 포함한 만성 질환의 유병률이 전 세계적으로 계속 증가함에 따라 병원은 이러한 치료에 대한 수요가 지속적으로 증가하고 있습니다. 병원은 진단 서비스, 치료, 치료 후 모니터링 등의 종합적인 치료를 제공하며, 이는 치료용 백신 치료를 받는 환자들에게 매우 중요합니다. 또한, 병원을 기반으로 한 연구 및 임상시험 증가는 이 분야의 치료용 백신 시장 확대에 기여하고 있습니다. 많은 치료용 백신이 병원 내에서 임상시험을 진행하기 때문에 의료진은 새로운 백신 및 치료법 개발에 대한 최신 정보를 얻을 수 있으며, 이는 치료용 백신 시장의 성장에 박차를 가하고 있습니다.

세계보건기구(WHO), Global Cancer Facts & Figures, 미국 암 협회 등은 치료용 백신 시장 보고서 작성 시 참고한 1차 및 2차 정보 중 하나입니다.

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 치료용 백신 시장 - 업계 상황

치료용 백신 시장 성장 전략
유기적 성장 전략
무기적 성장 전략

제12장 기업 개요

Dendreon
BioNTech SE
Serum Institute of India Pvt. Ltd
Merck & Co Inc
Amgen Inc
ISA Pharmaceuticals BV
INOVIO Pharmaceuticals Inc
Transgene SA
THERAVECTYS SA
CureVac SE

제13장 부록

LSH 25.03.19

The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Therapeutic Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Therapeutic Vaccines Market - Key Market Dynamics

5.1 Therapeutic Vaccines Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic Conditions
- 5.2.2 Increasing Investments and Funding for Vaccine Development
5.3 Market Restraints
- 5.3.1 Regulatory Challenges
5.4 Market Opportunities
- 5.4.1 Extending Product Pipeline
5.5 Future Trends
- 5.5.1 Advancements in Vaccine Technology
5.6 Impact of Drivers and Restraints:

6. Therapeutic Vaccines Market - Global Market Analysis

6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
6.2 Therapeutic Vaccines Market Forecast Analysis

7. Therapeutic Vaccines Market Analysis - by Product

7.1 Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
7.2 Infectious Disease Vaccines
- 7.2.1 Overview
- 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Therapeutic Vaccines Market Analysis - by Technology

8.1 Allogenic Vaccine
- 8.1.1 Overview
- 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
8.2 Autologous Vaccine
- 8.2.1 Overview
- 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Therapeutic Vaccines Market Analysis - by End User

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

10. Therapeutic Vaccines Market - Geographical Analysis

10.1 North America
- 10.1.1 North America Therapeutic Vaccines Market Overview
- 10.1.2 North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.1.2.1 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.1.2.2 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.1.2.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.1.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.1.3.1 United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
  - 10.1.3.2 Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
  - 10.1.3.3 Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
10.2 Europe
- 10.2.1 Europe Therapeutic Vaccines Market Overview
- 10.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.2.2.1 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.2.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.2.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.2 United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.3 France: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.4 Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.5 Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
10.3 Asia Pacific
- 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
- 10.3.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.3.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.2 Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.3 India: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.4 South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.5 Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
10.4 Middle East & Africa
- 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
- 10.4.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.4.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.2 South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
10.5 South & Central America
- 10.5.1 South & Central America Therapeutic Vaccines Market Overview
- 10.5.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.5.2.1 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.5.2.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.5.2.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.5.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
  - 10.5.3.2 Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
  - 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User

11. Therapeutic Vaccines Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Therapeutic Vaccines Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Dendreon
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 BioNTech SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Serum Institute of India Pvt. Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Merck & Co Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 ISA Pharmaceuticals BV
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 INOVIO Pharmaceuticals Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Transgene SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 THERAVECTYS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 CureVac SE
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

치료용 백신 시장 규모 및 예측(2021-2031년) : 세계 및 지역 점유율, 동향, 성장 기회 분석 - 제품별, 기술별, 최종사용자별, 지역별

Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 치료용 백신 시장 구도

제5장 치료용 백신 시장 - 주요 시장 역학

제6장 치료용 백신 시장 : 세계 시장 분석

제7장 치료용 백신 시장 분석 : 제품별

제8장 치료용 백신 시장 분석 : 기술별

제9장 치료용 백신 시장 분석 : 최종사용자별

제10장 치료용 백신 시장 : 지역별 분석